Related Experiment Video
Updated: Aug 19, 2026
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
Antisense oligonucleotides in the treatment of bladder cancer
Anthony J Glackin1, Sam B Gray, Samuel R Johnston
1Queen's University Belfast, Uro-oncology Group, Institute of Pathology, Grosvenor Road, Belfast, BT12 6BN, Northern Ireland. aglackin@doctors.org.uk.
Abstract:
This review examines the role that antisense oligonucleotides play in the treatment of superficial and muscle-invasive bladder cancer. The unique environment of the urinary bladder allows intravesical instillation of antisense oligonucleotides, and researchers have already demonstrated uptake of antisense oligonucleotides in models of bladder cancer. Second, proof of principle has been established by demonstrating downregulation of the antisense target mRNA and protein. Third, and most importantly from a therapeutic perspective, synergy between chemotherapy and antisense oligonucleotides has been shown in bladder cancer models in vitro and in vivo. The collective evidence points to a role for antisense oligonucleotides in the treatment of superficial and muscle-invasive bladder cancer in combination with existing treatment modalities.
Insights
Antisense oligonucleotides show promise for treating bladder cancer. These agents can be instilled directly into the bladder, reducing tumor cell growth and enhancing chemotherapy effectiveness in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Bladder cancer treatment remains a significant challenge, particularly for muscle-invasive forms.
- Antisense oligonucleotides (ASOs) represent a novel therapeutic strategy with potential applications in oncology.
- The unique anatomical and physiological characteristics of the urinary bladder facilitate targeted drug delivery.
Purpose of the Study:
- To review the potential of antisense oligonucleotides (ASOs) in treating superficial and muscle-invasive bladder cancer.
- To evaluate the feasibility of intravesical ASO instillation and its preclinical efficacy.
- To assess the synergistic effects of ASOs combined with chemotherapy for bladder cancer.
Main Methods:
- Review of preclinical studies and in vitro/in vivo bladder cancer models.
- Assessment of ASO uptake and distribution within bladder cancer models.
- Evaluation of mRNA and protein target downregulation by ASOs.
- Analysis of combination therapy effects with standard chemotherapy agents.
Main Results:
- Demonstrated successful intravesical instillation and uptake of ASOs in bladder cancer models.
- Confirmed proof-of-principle with significant downregulation of target mRNA and protein.
- Established synergistic effects between ASOs and chemotherapy in vitro and in vivo.
- Preclinical data support ASO efficacy in bladder cancer treatment.
Conclusions:
- Antisense oligonucleotides are a promising therapeutic option for bladder cancer.
- Intravesical ASO delivery is feasible and effective in preclinical settings.
- ASOs demonstrate synergy with chemotherapy, suggesting a role in combination treatment strategies for bladder cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...